Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
07 December 2017Website:
http://www.quanterix.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:02:44 GMTDividend
Analysts recommendations
Institutional Ownership
QTRX Latest News
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer's Disease (AD) in a broader range of patients. Recent Alzheimer's Association criteria for diagnosing Alzheimer's recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this app.
Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it. Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating.
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.16 per share a year ago.
The average price target suggests a potential increase of 67.7% for Quanterix (QTRX). Although studies show that this metric may not always be reliable, an increase in earnings estimates could indicate a positive outlook for the stock in the short term.
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024.
Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 1(current)
What type of business is Quanterix?
Quanterix Corporation develops an ultra-sensitive platform for digital immunoassay and tools for medical-biological research and diagnostics. The company offers a single molecule platform (Simoa) that uses single molecule measurements to detect protein biomarkers. The company also focuses on implementing and developing new treatment and diagnostic methods, making medical services easier for early detection, monitoring, prognosis, and ultimately disease prevention. Simoa specializes in research and clinical trials and significantly advances the enzyme-linked immunosorbent assay (ELISA) technology, providing unprecedented sensitivity in protein detection. Quanterix Corporation was founded in 2007, with its headquarters located in Billerica, Massachusetts.
What sector is Quanterix in?
Quanterix is in the Healthcare sector
What industry is Quanterix in?
Quanterix is in the Medical Devices industry
What country is Quanterix from?
Quanterix is headquartered in United States
When did Quanterix go public?
Quanterix initial public offering (IPO) was on 07 December 2017
What is Quanterix website?
https://www.quanterix.com
Is Quanterix in the S&P 500?
No, Quanterix is not included in the S&P 500 index
Is Quanterix in the NASDAQ 100?
No, Quanterix is not included in the NASDAQ 100 index
Is Quanterix in the Dow Jones?
No, Quanterix is not included in the Dow Jones index
When was Quanterix the previous earnings report?
No data
When does Quanterix earnings report?
The next expected earnings date for Quanterix is 06 November 2024